Matulonis, U. A., Wulf, G. M., Barry, W. T., Birrer, M., Westin, S. N., Farooq, S., . . . Winer, E. (2017). Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol.
Styl ChicagoMatulonis, U. A., et al. "Phase I Dose Escalation Study of the PI3kinase Pathway Inhibitor BKM120 and the Oral Poly (ADP Ribose) Polymerase (PARP) Inhibitor Olaparib for the Treatment of High-grade Serous Ovarian and Breast Cancer." Ann Oncol 2017.
Citace podle MLAMatulonis, U. A., et al. "Phase I Dose Escalation Study of the PI3kinase Pathway Inhibitor BKM120 and the Oral Poly (ADP Ribose) Polymerase (PARP) Inhibitor Olaparib for the Treatment of High-grade Serous Ovarian and Breast Cancer." Ann Oncol 2017.